Biotech IV Monitor

INSM — Insmed Incorporated

$28.5B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Insmed Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts55 Phase 3
Market cap$28.5B
Cash & investments$1.15B~11 quarters at last loss rate
Recent 8-K filings1latest 2026-10-29

Upcoming readouts

Phase 2/3 Treprostinil Palmitil
Pulmonary Arterial Hypertension · NCT05649748
December 2026
Ongoing
Phase 3 Treprostinil Palmitil Inhalation Powder
Pulmonary Arterial Hypertension · NCT07481981
December 2028
Recruiting
Phase 3 Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension; Interstitial Lung Disease · NCT07179380
December 2028
Recruiting
Phase 3 Treprostinil Palmitil Inhalation Powder
Progressive Pulmonary Fibrosis; Interstitial Lung Disease · NCT07805785
August 2030
Recruiting
Phase 3 Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension; Interstitial Lung Disease · NCT07234032
January 2031
Recruiting

Cash position

Insmed Incorporated reported $1.15B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $100M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow INSM, you can start the conversation.
Track INSM in real time
See live implied volatility for INSM and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on INSM
Contact — questions or corrections about INSM: dukeupt@gmail.com